Summit Therapeutics Inc.
SMMT
Helyezés a részvények között
#1665
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Részvényárfolyam
$16.12
Piaci kapitalizáció
$12.86B
Változás (1 nap)
0.17%
Változás (1 év)
-14.00%
Ország
US
Kereskedés Summit Therapeutics Inc. (SMMT)
Kategória
Healthcare
Summit Therapeutics Inc. (SMMT) P/B aránya
P/B arány ekkor: October 2026 TTM: 18.69
Summit Therapeutics Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi könyv szerinti árfolyam aránya (P/B, TTM) 18.69. 2023 végén ez az arány 20.82 volt.
P/B arány története a(z) Summit Therapeutics Inc. esetén 2004 és 2026 között
P/B arány az év végén
| Év | P/B arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 18.69 | -43.35% |
| 2024 | 32.99 | 58.49% |
| 2023 | 20.82 | 220.87% |
| 2022 | 6.49 | 117.76% |
| 2021 | 2.98 | -27.56% |
| 2020 | 4.11 | 536.54% |
| 2019 | 0.65 | -98.56% |
| 2018 | 45.00 | -138.35% |
| 2017 | -117.33 | -1,034.33% |
| 2016 | 12.56 | 5.70% |
| 2015 | 11.88 | -48.78% |
| 2014 | 23.20 | 2.85% |
| 2013 | 22.55 | 13.41% |
| 2012 | 19.89 | -52.35% |
| 2011 | 41.73 | 29.00% |
| 2010 | 32.35 | 6.43% |
| 2009 | 30.39 | 569.58% |
| 2008 | 4.54 | -3.53% |
| 2007 | 4.71 | -38.65% |
| 2006 | 7.67 | 60.25% |
| 2005 | 4.79 | -99.36% |
| 2004 | 747.02 | 0.00% |
P/B arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/B arány | P/B arány különbség | Ország |
|---|---|---|---|
| 6.251 | -66.55% |
US
|
|
| 13.2547 | -29.08% |
US
|
|
| 4.208 | -77.48% |
AU
|
|
| 6.1824 | -66.92% |
NL
|
|
| - | - |
CH
|
